Immunara Therapeutics
Directing immunity, better patient outcomes
Harnessing immunity
Immunara is developing a novel precision immunotherapy that aims to train the immune system to recognise and eliminate dangers specifically and more effectively.Our approach focuses on selectively delivering immunotherapy components to antigen-presenting cells (APCs) — the ‘teacher cells’ of the immune system that are essential for triggering targeted immune responses using our patented single domain antibodies (SdAb) carriers.By guiding antigens or immunomodulators directly to the right immune cells, our technology has the potential to unlock stronger and highly specific responses against cancer or other diseases.
The Team
Born as a spinout from Amsterdam UMC, Immunara brings together deep academic insight with industry expertise: scientific co-founders pioneering this technology, clinical researchers, a pharmaceutical R&D leader, experienced business developers — all driven by one goal: transforming academic discoveries into effective immunotherapies and successful ventures.Together, we envision Immunara as a next-generation platform advancing targeted and personalized immunotherapy for cancer and other immune-mediated diseases.
Supported by
This initiative is supported by multiple programs and funding instruments including the NWO Faculty of Impact, Take-Off, Venture Challenge, KWF Dutch Cancer Society, and Innovation Exchange Amsterdam (IXA).
Partner with us
Immunara is currently seeking strategic partnerships and investment to accelerate preclinical development and expand our platform toward multiple cancer indications and immune-mediated diseases.
We welcome collaborations with academic groups, biotech companies, and investors who share our vision for the future of targeted immunotherapy.